657 related articles for article (PubMed ID: 17892918)
21. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?
Fukunaga-Johnson N; Lee JH; Sandler HM; Robertson P; McNeil E; Goldwein JW
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):143-6. PubMed ID: 9747831
[TBL] [Abstract][Full Text] [Related]
22. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.
Okada K; Soejima T; Sakamoto H; Hirato J; Hara J
Pediatr Blood Cancer; 2020 Nov; 67(11):e28572. PubMed ID: 32710713
[TBL] [Abstract][Full Text] [Related]
25. Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy.
Sirachainan N; Nuchprayoon I; Thanarattanakorn P; Pakakasama S; Lusawat A; Visudibhan A; Dhanachai M; Larbcharoensub N; Amornfa J; Shotelersuk K; Katanyuwong K; Tangkaratt S; Hongeng S
J Clin Neurosci; 2011 Apr; 18(4):515-9. PubMed ID: 21310618
[TBL] [Abstract][Full Text] [Related]
26. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK; Palmer SL; Merchant TE; Wallace D; Kocak M; Brouwers P; Krull K; Chintagumpala M; Stargatt R; Ashley DM; Tyc VL; Kun L; Boyett J; Gajjar A
J Clin Oncol; 2005 Aug; 23(24):5511-9. PubMed ID: 16110011
[TBL] [Abstract][Full Text] [Related]
27. Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma.
Korah MP; Esiashvili N; Mazewski CM; Hudgins RJ; Tighiouart M; Janss AJ; Schwaibold FP; Crocker IR; Curran WJ; Marcus RB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):106-12. PubMed ID: 19695790
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma.
Jakacki RI; Feldman H; Jamison C; Boaz JC; Luerssen TG; Timmerman R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):531-6. PubMed ID: 15380589
[TBL] [Abstract][Full Text] [Related]
29. Low-dose craniospinal radiation therapy for medulloblastoma.
Halberg FE; Wara WM; Fippin LF; Edwards MS; Levin VA; Davis RL; Prados MB; Wilson CB
Int J Radiat Oncol Biol Phys; 1991 Apr; 20(4):651-4. PubMed ID: 2004939
[TBL] [Abstract][Full Text] [Related]
30. Medulloblastoma: time-dose relationship based on a 30-year review.
del Charco JO; Bolek TW; McCollough WM; Maria BL; Kedar A; Braylan RC; Mickle JP; Buatti JM; Mendenhall NP; Marcus RB
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):147-54. PubMed ID: 9747832
[TBL] [Abstract][Full Text] [Related]
31. Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival.
Eaton BR; Esiashvili N; Kim S; Weyman EA; Thornton LT; Mazewski C; MacDonald T; Ebb D; MacDonald SM; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):133-138. PubMed ID: 26700707
[TBL] [Abstract][Full Text] [Related]
32. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
[TBL] [Abstract][Full Text] [Related]
33. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
[TBL] [Abstract][Full Text] [Related]
34. [Medulloblastomas--the results after postoperative radiotherapy with and without adjuvant chemotherapy].
Grabenbauer GG; Löhnert C; Erhardt J; Buchfelder M; Neubauer U; Beck JD; Reitz S; Seyer H; Thierauf P; Fietkau R
Strahlenther Onkol; 1993 Apr; 169(4):213-21. PubMed ID: 8488458
[TBL] [Abstract][Full Text] [Related]
35. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy.
Ricardi U; Corrias A; Einaudi S; Genitori L; Sandri A; di Montezemolo LC; Besenzon L; Madon E; Urgesi A
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1287-94. PubMed ID: 11483340
[TBL] [Abstract][Full Text] [Related]
36. Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma.
Tian S; Sudmeier LJ; Zhang C; Madden NA; Buchwald ZS; Shu HG; Curran WJ; Eaton BR; Esiashvili N
Pediatr Blood Cancer; 2020 Jan; 67(1):e28027. PubMed ID: 31571408
[TBL] [Abstract][Full Text] [Related]
37. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
[TBL] [Abstract][Full Text] [Related]
38. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma.
Liu KX; Ioakeim-Ioannidou M; Susko MS; Rao AD; Yeap BY; Snijders AM; Ladra MM; Vogel J; Zaslowe-Dude C; Marcus KJ; Yock TI; Grassberger C; Braunstein SE; Haas-Kogan DA; Terezakis SA; MacDonald SM
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):726-735. PubMed ID: 33243479
[TBL] [Abstract][Full Text] [Related]
39. Importance of radiation time and dose factors on outcome for childhood medulloblastoma.
Back M; Ahern V; Berry M; Borg M; Sexton M; Cameron F; Stevens G; Allison R; Childs J; Barton M
Australas Radiol; 2005 Aug; 49(4):298-303. PubMed ID: 16026436
[TBL] [Abstract][Full Text] [Related]
40. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation.
Thomas PR; Deutsch M; Kepner JL; Boyett JM; Krischer J; Aronin P; Albright L; Allen JC; Packer RJ; Linggood R; Mulhern R; Stehbens JA; Langston J; Stanley P; Duffner P; Rorke L; Cherlow J; Friedman HS; Finlay JL; Vietti TJ; Kun LE
J Clin Oncol; 2000 Aug; 18(16):3004-11. PubMed ID: 10944134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
